Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.
Recruitment status was Recruiting
Various methods of FDG-PET signal segmentation will be validated by correlation of histopathologically measured tumor dimensions in lymph node dissection specimens of head-and-neck cancer patients.
|Official Title:||Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.|
- How accurate are the various FDG-PET segmentation tools? [ Time Frame: Measurements are performed in conjunction with the clinical pathologist directly postoperatively. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Head-and-neck cancer patients will undergo a therapeutic lymph node dissection of the cervical nodes. This treatment is given whether the patient is enrolled in the study or not. Histological specimens of cancer patients are always stored for possible future refference in the routine clinical practice.
|Study Start Date:||July 2008|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
Head-and-neck cancer patients.
Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
Other: CT-FDG/PET scan of the head-and-neck region
CT-FDG/PET scan of the head-and-neck region
Please refer to this study by its ClinicalTrials.gov identifier: NCT00782691
|Contact: Dominic A.X. Schinagl, MD||NL24firstname.lastname@example.org|
|Radboud University Nijmegen Medical Centre||Recruiting|
|Nijmegen, Gelderland, Netherlands, 6500HB|
|Principal Investigator: Dominic AX Schinagl, MD|